SARS-CoV-2 is a novel coronavirus that emerged in China at the end of 2019 causing the
severe disease known as coronavirus disease 2019 (COVID-19). SARS-CoV-2, as to the …

Messenger RNA (mRNA) vaccine development for preventive and therapeutic applications
has evolved rapidly over the last decade. The mRVNA vaccine has proven therapeutic …

The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-
generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the …

). First isolated in late November of 2021, the Omicron variant harbors a staggering 30–40
mutations in the viral spike (S) protein, including substantial changes to the S-receptor …

The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …

Abstract Since Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was
identified in late 2019, the coronavirus disease 2019 (COVID-19) pandemic has challenged …

RNA viruses generate defective viral genomes (DVGs) that can interfere with replication of
the parental wild-type virus. To examine their therapeutic potential, we created a DVG by …

Vaccines are a highly effective intervention for conferring protection against infections and
reducing the associated morbidity and mortality in vaccinated individuals. However, ageing …

Elderly people are particularly vulnerable to COVID-19, with a high risk of developing severe
disease and a reduced immune response to the COVID-19 vaccine. A randomized, placebo …

Antibody production following vaccination can provide protective immunity to subsequent
infection by pathogens such as influenza viruses. However, circumstances where antibody …